Kailera Therapeutics Files S-1/A Amendment
Ticker: KLRA · Form: S-1/A · Filed: Apr 13, 2026
Sentiment: neutral
Topics: sec-filing, s-1/a, registration
TL;DR
Kailera Therapeutics filed an S-1/A on 4/13/26. Details on offering to come.
AI Summary
Kailera Therapeutics, Inc. filed an S-1/A amendment on April 13, 2026, to register securities. The filing includes various exhibits such as the company's charter, bylaws, and material contracts, but does not disclose specific financial figures or offering details in this amendment.
Why It Matters
This S-1/A filing indicates Kailera Therapeutics is moving forward with its plan to offer securities to the public, which could lead to significant capital infusion or dilution for existing shareholders.
Risk Assessment
Risk Level: medium — As an S-1/A filing, it signifies a company preparing to go public or raise capital, which inherently carries market and execution risks.
Key Players & Entities
- Kailera Therapeutics, Inc. (company) — Filer of the S-1/A
- 0002096997 (company) — CIK number for Kailera Therapeutics, Inc.
- 0001193125-26-151904 (filing_id) — SEC Accession Number for the filing
- 2026-04-13 (date) — Filing Date
FAQ
What is the purpose of this S-1/A filing by Kailera Therapeutics, Inc.?
The S-1/A filing is an amendment to the registration statement for securities under the Securities Act of 1933, indicating Kailera Therapeutics, Inc. is proceeding with its public offering plans.
When was this S-1/A amendment filed with the SEC?
This S-1/A amendment was filed on April 13, 2026.
Does this filing contain specific financial details of the offering?
This particular S-1/A filing is an amendment and primarily consists of exhibits and updated registration information; specific financial details of the offering are not explicitly detailed within the provided summary of documents.
What types of exhibits are included with this S-1/A filing?
The filing includes exhibits such as EX-3.1 (Articles of Incorporation), EX-3.3 (Bylaws), EX-5.1 (Legal Opinion), and various material contracts (EX-10.2, EX-10.3, EX-10.4, EX-10.9), among others.
What is the SEC Accession Number for this filing?
The SEC Accession Number for this filing is 0001193125-26-151904.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on April 13, 2026 regarding Kailera Therapeutics, Inc. (KLRA).